Annual report pursuant to Section 13 and 15(d)


12 Months Ended
Dec. 31, 2019
Leases [Abstract]  

9. Leases


In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which establishes a ROU model that requires a lessee to record a ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. Effective January 1, 2019, the Company adopted the provisions of Topic 842 using the alternative modified transition method, with a cumulative effect adjustment to the opening balance of accumulated deficit on the date of adoption, and prior periods not restated, as allowed under the provisions of Topic 842. The Company also elected to use the practical expedients permitted under the transition guidance of Topic 842, which provides for the following: the carryforward of the Company’s historical lease classification, no requirement for reassessment of whether an expired or existing contract contains an embedded lease, no reassessment of initial direct costs for any leases that exist prior to the adoption of the new standard, and the election to consolidate lease and non-lease components. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet.


The Company recorded $2.4 million of right-of-use lease assets and $2.5 million of lease liabilities upon adoption, primarily relating to rentals of space for our corporate headquarters and laboratories, as well as equipment leases, all under operating leases. In addition, the Company recorded a cumulative adjustment to opening accumulated deficit of $0.1 million. With the acquisition of the Biopharma business of CGI in 2019, the Company added $2.2 million of operating lease assets and liabilities and $0.5 million of finance lease assets and liabilities to its balance sheet. Finance lease assets are included in fixed assets, net of accumulated depreciation.


The table below presents the lease-related assets and liabilities recorded in the Consolidated Balance Sheet:


    Classification on the Balance Sheet   December 31, 2019  
Financing lease assets   Property and equipment, net   $ 998  
Operating lease assets   Operating lease right of use assets     3,892  
Total lease assets       $ 4,890  
Financing lease liabilities   Other accrued expenses   $ 184  
Operating lease liabilities   Other accrued expenses     1,321  
Total current lease liabilities       $ 1,505  
Financing lease liabilities   Other long-term liabilities     123  
Operating lease liabilities   Operating lease liabilities, net of current portion     2,591  
Total long-term lease liabilities         2,714  
Total lease liabilities       $ 4,219  


The weighted average remaining lease term for the Company’s operating leases was 2.7 years as of December 31, 2019 and the weighted average discount rate for those leases was 6.0%. The Company’s operating lease expenses are recorded within cost of revenue and general and administrative expenses.


The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019:


    Operating Leases     Financing Leases  
2020     1,472       226  
2021     1,295       120  
2022     1,223       13  
2023     344       -  
Total minimum lease payments     4,334       359  
Less: amount of lease payments representing effects of discounting     418       52  
Present value of future minimum lease payments     3,916       307  
Less: current obligations under leases     1,321       184  
Long-term lease obligations   $ 2,595     $ 123